BDX Files 8-K: Debt Maturities and Financial Exhibits
Ticker: BDX · Form: 8-K · Filed: Jun 3, 2024 · CIK: 10795
| Field | Detail |
|---|---|
| Company | Becton Dickinson & CO (BDX) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $1.00 B, $4.2 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, financial-reporting, disclosure
Related Tickers: BDX
TL;DR
BDX dropped an 8-K with debt details - check the maturity dates!
AI Summary
On June 3, 2024, Becton, Dickinson and Company (BDX) filed an 8-K report detailing its financial statements and exhibits. The filing includes information on various debt instruments, such as notes due December 15, 2026, May 24, 2025, June 4, 2026, February 12, 2036, August 13, 2025, February 8, 2031, and other unspecified dates. This report serves as a current update on the company's financial disclosures.
Why It Matters
This filing provides investors with updated information on Becton Dickinson's outstanding debt obligations and financial reporting, crucial for assessing the company's financial health and future borrowing capacity.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks to the company.
Key Numbers
- 2026 — Debt Maturity Year (Notes due December 15, 2026, and June 4, 2026)
- 2025 — Debt Maturity Year (Notes due May 24, 2025, and August 13, 2025)
- 2031 — Debt Maturity Year (Notes due February 8, 2031)
- 2036 — Debt Maturity Year (Notes due February 12, 2036)
Key Players & Entities
- BECTON DICKINSON & CO (company) — Registrant
- BDX (company) — Ticker Symbol
- June 3, 2024 (date) — Report Date
- New Jersey (location) — State of Incorporation
- Notes 1.900 due December 15 2026 (dollar_amount) — Debt Instrument
- Notes 3.020 due May 24 2025 (dollar_amount) — Debt Instrument
- Notes 1.208 due June 4 2026 (dollar_amount) — Debt Instrument
- Notes 1213 Due February 12 2036 (dollar_amount) — Debt Instrument
- Notes 0034 Due August 13 2025 (dollar_amount) — Debt Instrument
- Notes 3.519 Due February 8 2031 (dollar_amount) — Debt Instrument
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as well as to provide a Regulation FD Disclosure.
What specific debt instruments are mentioned in the filing?
The filing mentions several debt instruments including notes due December 15, 2026 (1.900%), May 24, 2025 (3.020%), June 4, 2026 (1.208%), February 12, 2036 (12.13%), August 13, 2025 (0.34%), and February 8, 2031 (3.519%).
When was this 8-K report filed?
This 8-K report was filed on June 3, 2024.
What is Becton, Dickinson and Company's state of incorporation?
Becton, Dickinson and Company's state of incorporation is New Jersey.
What is the ticker symbol for Becton, Dickinson and Company?
The ticker symbol for Becton, Dickinson and Company is BDX.
Filing Stats: 938 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-06-03 06:33:34
Key Financial Figures
- $1.00 B — ch registered Common stock, par value $1.00 BDX New York Stock Exchange 1.900% Notes
- $4.2 billion — r in advanced monitoring solutions, for $4.2 billion in cash. A copy of the press release is
Filing Documents
- bdx-20240603.htm (8-K) — 43KB
- bd_newsxcriticalxcarexacqu.htm (EX-99.1) — 22KB
- projecttitansell-sidedec.htm (EX-99.2) — 9KB
- image_0a.jpg (GRAPHIC) — 135KB
- projecttitansell-sidedec001.jpg (GRAPHIC) — 75KB
- projecttitansell-sidedec002.jpg (GRAPHIC) — 247KB
- projecttitansell-sidedec003.jpg (GRAPHIC) — 132KB
- projecttitansell-sidedec004.jpg (GRAPHIC) — 104KB
- projecttitansell-sidedec005.jpg (GRAPHIC) — 117KB
- projecttitansell-sidedec006.jpg (GRAPHIC) — 111KB
- 0000010795-24-000044.txt ( ) — 1560KB
- bdx-20240603.xsd (EX-101.SCH) — 4KB
- bdx-20240603_def.xml (EX-101.DEF) — 19KB
- bdx-20240603_lab.xml (EX-101.LAB) — 35KB
- bdx-20240603_pre.xml (EX-101.PRE) — 20KB
- bdx-20240603_htm.xml (XML) — 8KB
01. Regulation FD Disclosure
ITEM 7.01. Regulation FD Disclosure. On June 3, 2024, Becton, Dickinson and Company ("BD"), a leading global medical technology company, issued a press release announcing a definitive agreement under which BD will acquire Edwards Lifesciences' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash. A copy of the press release is furnished hereto as Exhibit 99.1. A slide presentation regarding the transaction is available on the News & Events page of BD's investor website at https://investors.bd.com/news-events and is furnished hereto as Exhibit 99.2. The information in this Item 7.01, including the exhibits furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Forward Looking Statements
Forward Looking Statements This report contains certain forward-looking statements (as defined under Federal securities laws). Forward looking statements generally are accompanied by words such as "will", "expect", or similar words, phrases or expressions. These forward-looking statements include statements regarding the estimated or anticipated future results of BD and anticipated benefits of the proposed acquisition of Critical Care, the expected timing of completion of the transaction, future growth in Critical Care's relevant market segments, and other statements that are not historical facts. These statements are based on the current expectations of BD management and are subject to a number of risks and uncertainties regarding Critical Care's business and the proposed acquisition, and actual results may differ materially from any anticipated results described, implied or projected in any forward-looking statement. These risks and uncertainties include, but are not limited to, the ability of the parties to successfully close the proposed acquisition, including the risk that the required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transaction; risks relating to the integration of Critical Care's operations, products and employees into BD and the time and resources required to do so and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; the loss of key senior management or other associates; competitive factors, including the development of new technologies by other companies and pricing and market share pressures; changes in healthcare or other governmental regulation; risks relating to the ability to maintain favorable supplier arrangements and relationships; changes in regional, national or foreign economic conditi
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 Press release dated June 3, 2024, which is furnished pursuant to Item 7.01. Exhibit 99.2 Presentation, dated June 3, 2024, which is furnished pursuant to Item 7.01. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BECTON, DICKINSON AND COMPANY (Registrant) By: /s/ Gary DeFazio Gary DeFazio Senior Vice President and Corporate Secretary Date: June 3, 2024